Sep 16, 2003

Nitric oxide synthase inhibition depresses the height of the cerebral blood flow-pressure autoregulation curve during moderate hypotension

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
Stephen C JonesAlejandro D Perez-Trepichio

Abstract

Variations in the height of the CBF response to hypotension have been described recently in normal animals. The authors evaluated the effects of nitric oxide synthase (NOS) inhibition on these variations in height using laser Doppler flowmetry in 42 anesthetized (halothane and N2O) male Sprague-Dawley rats prepared with a superfused closed cranial window. In four groups (time control, enantiomer control, NOS inhibition, and reinfusion control) exsanguination to MABPs from 100 to 40 mm Hg was used to produce autoregulatory curves. For each curve the lower limit of autoregulation (the MABP at the first decrease in CBF) was identified; the pattern of autoregulation was classified as "peak" (15% increase in %CBF), "classic" (plateau with a decrease at the lower limit of autoregulation), or "none" (15% decrease in %CBF); and the autoregulatory height as the %CBF at 70 mm Hg (%CBF(70)) was determined. NOS inhibition decreased %CBF(70) in the NOS inhibition group (P = 0.014), in the control (combined time and enantiomer control) group (P = 0.015), and in the reinfusion control group (P = 0.025). NOS inhibition via superfusion depressed the autoregulatory pattern (P = 0.02, McNemar test on changes in autoregulatory pattern) compared wi...Continue Reading

  • References21
  • Citations13
  • References21
  • Citations13

Citations

Mentioned in this Paper

Diastolic Blood Pressure
Regional Blood Flow
Nitroarginine
Cerebrovascular Circulation
Nitric Oxide Synthase
Enzyme Inhibitors
Velocimetry, Laser-Doppler
Rats, Holtzman
Hypotension
Alloenzymes

Related Feeds

Alzheimer's Disease: Endosomes

The feed focuses on the role of dysfunctional endosomal trafficking in Alzheimer’s Disease and the potential for targeting the endosome as a therapeutic target.